CD274 and neoplasm: Nonetheless, PD-1 inhibitors were reported to unleash anti-tumor immunity and achieve durable clinical responses in only 15–20% of treated patients in front-line recurrent/metastatic (R/M) setting5–8, with 4-year overall survival rate of about 15% overall and up to 22% among cases with a PD-L1 combined positive score (CPS) of 20 or greater5–9.